WAVEMAN · COMPANY

ADMA · Adma Biologics, Inc.

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475

← ALL COMPANIES

ADMA

Name: ADMA BIOLOGICS, INC. (ADMA) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

ADMA BIOLOGICS, INC.

PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0001368514

SEC FILINGS☆ WATCH

INSIDER NET · 180D

-$225.3K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

147

13F, latest reported quarter

REVENUE GROWTH

+19.6%

XBRL, annual

NET MARGIN

28.8%

CONVERSIONS · 180D

codes C/M, not in net · $223.1K priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$225.3K over 180 days

more than 51% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

147 funds added or opened last quarter

more than 78% of Pharma & Biotech

REVENUE

+19.6% year over year

more than 68% of Pharma & Biotech

MARGIN

28.8% net margin

more than 92% of Pharma & Biotech

BUYBACKS

$155.2M repurchased, FY to 2026-06-30

more than 72% of Pharma & Biotech

SHORT

9.8% of shares outstanding short · 8.8 days to cover · settled 2026-07-31

more than 76% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

147 funds added or opened positions in the latest 13F quarter, of 326 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -44.3%

-44.3%12M

INSIDER BUYINSIDER SELL

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows a net $225.3K sold by insiders over 180 days, 147 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, ADMA BIOLOGICS, INC. insiders sold a net $225.3K of stock across 76 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER

FILED

VALUE

Grossman Jerrold B

Director

BUY

2026-05-27

6,400.0

$50.6K

Grossman Jerrold B

Director

BUY

2026-05-12

12,500.0

$100.1K

Grossman Jerrold B

Director

BUY

2026-05-11

12,500.0

$100.1K

Grossman Adam S

President and CEO

SELL

2026-03-16

6,000.0

$91.0K

Grossman Adam S

President and CEO

SELL

2026-03-16

15,000.0

$227.4K

76 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 71 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

38,355,684.0 sh

$321.0M

STATE STREET CORP

17,116,022.0 sh

$143.3M

VANGUARD CAPITAL MANAGEMENT LLC

10,103,809.0 sh

$84.6M

VANGUARD PORTFOLIO MANAGEMENT LLC

10,088,490.0 sh

$84.4M

Rubric Capital Management LP

9,339,414.0 sh

$78.2M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Motley Fool Small-Cap Growth ETF

$1.7M POSITION · AS OF 2026-02-28

2.4%

Invesco S&P SmallCap Health Care ETF

$3.1M POSITION · AS OF 2026-02-28

2.2%

Transamerica Small Cap Growth

$1.2M POSITION · AS OF 2026-04-30

1.5%

Ranger Small Cap Fund

$326.4K POSITION · AS OF 2026-04-30

1.5%

Ranger Micro Cap Fund

$170.5K POSITION · AS OF 2026-04-30

1.5%

Nationwide Renaissance Small Cap Growth Fund

$344.3K POSITION · AS OF 2026-04-30

1.4%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 2 registered trials, 0 still enrolling or running — a status change here is dated weeks before the press release

Phase 4

0 ACTIVE

Not applicable

0 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$510.2M	$426.5M	$258.2M	$154.1M
GROSS PROFIT	$292.8M	$219.6M	$88.9M	$35.3M
OPERATING INCOME	$191.4M	$139.0M	$21.6M	$-39.4M
NET INCOME	$146.9M	$197.7M	$-28.2M	$-65.9M
EPS (DILUTED)	0.60	0.81	-0.13	-0.33
OPERATING CASH FLOW	$50.4M	$118.7M	$8.8M	$-59.5M
CASH	$87.6M	$103.1M	$51.4M	$86.5M
LONG-TERM DEBT	$69.3M	$72.3M	—	—
BUYBACKS	$31.9M	$0	$0	—

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE